Traffic Lights - Latest Updates

Last updated: 21/08/2017

Other updates on this site
Drug Name Classification Clinical Indication Comments
APREMILAST (Otezla®) (NEW) Red Psoriasis

In line with NICE TA 419

APREMILAST (Otezla®) (UPDATED) Red Psoriatic arthritis

In line with NICE TA 433

CALCIPOTRIOL/BETAMETHASONE CUTANEOUS FOAM (Enstilar®) (UPDATED) Green Psoriasis vulgaris

Management of Psoriasis in Primary Care

CERTOLIZUMAB PEGOL (NEW) Red Psoriatic arthritis

In line with NICE TA 445

DACLIZUMAB (UPDATED) Red Relapsing forms of multiple sclerosis

In line with NICE TA 441

ELBASVIR/GRAZOPREVIR (Zepatier) (NEW) Red Hepatitis C

In line with NICE TA 413

ETELCALCETIDE injection (Parsabiv) (NEW) Black Secondary hyperparathyroidism in adult patients with chronic kidney disease on haemodialysis therapy

Not yet reviewed

FLUNARIZINE (NEW) Red Migraine prophylaxis in adults
FLUTICASONE / AZELASTINE NASAL SPRAY (Dymista®) (UPDATED) Green Rhinitis

To be used in line with the Allergic Rhinitis Pathway

FLUTICASONE / VILANTEROL INHALER (Relvar®) (UPDATED) Black Asthma

Reviewed by LLR Respiratory Prescribing Group, deemed not appropriate for review by TAS

FLUTICASONE/ SALMETEROL XINAFOATE INHALER (AirFluSal Forspiro®) (NEW) Black COPD and Asthma

Reviewed by LLR Respiratory Prescribing Group, deemed not appropriate for review by TAS

INSULIN GLARGINE (Toujeo® 300units per ml) (UPDATED) Green Diabetes mellitus in adults

UKMI – Product Safety Assessment Report
MUST BE PRESCRIBED BY BRAND NAME

INSULIN LISPRO (Humalog®) U200 (NEW) Green Conditional Diabetes Mellitus

Conditional on prescriber being competent to select appropriate patients

INSULIN LISPRO (Humalog®) U200 (NEW) Amber Simple Diabetes Mellitus

Amber if GP does not feel competent to initiate.

IXEKIZUMAB (NEW) Red Psoriasis

In line with NICE TA 442

LIDOCAINE/PRILOCAINE cutaneous spray (Fortacin) (NEW) Black Primary premature ejaculation

Not yet reviewed

OBETICHOLIC ACID (NEW) Red Primary Biliary cholangitis

In line with NICE TA 443

OLMESARTAN/AMLODIPINE/HYDROCHLOROTHIAZIDE (Sevikar HCT) (NEW) Black Non-adherence due to polypharmacy
RIFAMPICIN/ISONIAZID/PYRAZINAMIDE/ETHAMBUTOL (Voractiv) (NEW) Red Tuberculosis
SAFINAMIDE (Xadago®) (NEW) Red Parkinson’s Disease
SECUKINUMAB Red Psoriatic arthritis

In line with NICE TA 445

SUCROFERRIC OXYHYDROXIDE (Velphoro®) (NEW) Red Treatment/prevention of hyperphosphataemia of chronic kidney disease

Other Updates on this Website

Recent documents from LMSG and TAS

About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more